Naoto T Ueno: The Impact of Enhertu on Quality of Life
Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared an article on X:
“The DESTINY-Breast04 study highlights a critical issue—persistent, subtle nausea and fatigue that patients experience compared to standard chemotherapy.
Read the papers for details. That’s why patients have shared concerns about the impact of Enhertu (T-DXd) on quality of life.”
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC.
Authors: Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Yeon Hee Park, Hope S Rugo, Binghe Xu, Fatima Cardoso, Zahi Mitri, Reshma Mahtani, Cecilia Orbegoso Aguilar, Feng Xiao, Nadia Harbeck, David A Cameron, Shanu Modi.
You can read the Full Article on Journal of The Oncologist.
More posts featuring Naoto T Ueno.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023